Can you explain what Myomaker Bio's lab-grown human muscle platform is and the challenge it aims to address in drug development? Myomaker Bio develops three-dimensional human-derived muscle organs and ...

Life sciences have never been more digital. To learn more about life processes, biologists are collecting massive quantities of data that computer scientists analyze by means of sophisticated ...

The “atrofish” reveals early triggers of sarcopenia and links muscle loss to nerve degeneration, establishing a platform for comparative research on muscle aging and potential therapies As people age, ...

Stimulating muscle fibers with magnets causes them to grow in the same direction, aligning muscle cells within tissue. The findings offer a simpler, less time-consuming way for medical researchers to ...

Muscle atrophy is a primary characteristic of both sarcopenia and cachexia, significantly impacting physical function and quality of life. This figure illustrates the multifaceted causes of muscle ...

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

Investigators are constantly aiming to identify new therapeutic approaches for regenerative medicine. Recent strategies have focused on harnessing the power of the body's own tissue healing and repair ...

Muscle loss is a well-publicized side effect of GLP-1 drugs, prompting a surge of interest in ingredients that can attenuate ...

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, ...